Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 27 CNS 3 Endocrine 2 Tumor-Agnostic 1 Gynecologic 1 Breast 1

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 696 Paclitaxel 679 Cyclophosphamide 634 Docetaxel 554 Capecitabine 468 Letrozole 407 Carboplatin 393 Fulvestrant 379 Doxorubicin 330 Tamoxifen 288 pembrolizumab 272 Anastrozole 252 Epirubicin 249 exemestane 238 pertuzumab 229 Bevacizumab 214 Radiotherapy 213 Gemcitabine 211 Vinorelbine 188 palbociclib 183 Lapatinib 175 130-nm albumin-bound paclitaxel 168 Albumin-Bound Paclitaxel 156 Exercise 147 Magnetic Resonance Spectroscopy 145 eribulin 144 Taxes 134 Fluorouracil 131 Everolimus 118 Cisplatin 118

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × belzutifan × Breast × Clear all

NCT06428396 2026-05-18

LITESPARK-029

Merck Sharp & Dohme LLC

Phase 2 Recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡